Antibiotics Market Size

Antibiotics Market size was valued at USD 52.67 Billion in 2023 and is poised to grow from USD 54.83 Billion in 2024 to USD 75.63 Billion by 2032, growing at a CAGR of 4.10% during the forecast period (2025-2032).

'Pfizer Inc. (US) ', 'GlaxoSmithKline plc. (GSK) (UK) ', 'Sanofi S.A. (France) ', 'Merck & Co., Inc. (US) ', 'Novartis AG (Switzerland) ', 'Johnson & Johnson (US) ', 'F. Hoffmann-La Roche AG (Switzerland) ', 'AstraZeneca PLC (UK) ', 'Bayer AG (Germany) ', 'Abbott Laboratories (US) ', 'Eli Lilly and Company (US) ', 'Bristol-Myers Squibb Company (US) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Astellas Pharma Inc. (Japan) ', 'Cipla Ltd (India) ', 'AbbVie, Inc. (US) ', 'Lupin Pharmaceuticals, Inc. (US) ', 'Viatris, Inc. (US) ', 'Melinta Therapeutics LLC (US) ', 'Cipla, Inc. (US) ', 'Shionogi & Co., Ltd. (Japan) ', 'KYORIN Pharmaceutical Co., Ltd. (Japan) ', 'Nabriva Therapeutics PLC (Ireland)'

Increasing incidence of infectious diseases across the globe is one of the major drivers of the antibiotics market. Respiratory infections, TB, urinary tract infections, sexually transmitted diseases infections (STDs) are some of the major antibiotic-treated diseases increased in addition to multidrug resistant. With the emergence of strains, health care providers are seeking new, more potent antibiotics to overcome these challenges. 

Increased Focus on Narrow-spectrum Antibiotics: A growing trend in the antibiotics market is the shift from broad-spectrum antibodies to narrow-spectrum drugs broad-spectrum antibiotics affect a wide range of bacteria and can cause side effects and lead to resistance. However, narrow-spectrum antibiotics target specific bacterial species, reduce the risk of the resistance, and maintain the balance of healthy bacteria in the body. 

Asia Pacific dominated the market and accounted for 43.8% of the revenue in the region owing to rise in infectious diseases, rise in dispensing of non-prescription drugs, presence of well-established hospitals & clinics. According to a University of Oslo article published in May 2023, the main suppliers of antibiotics are India and China. Antibiotics and antimicrobial products from both countries are of great importance to the world. China is the world’s leading producer and manufacturer of antibiotics. Similarly, according to a BBC news article published in September 2023, national data shows that out of 29.1% of the 125 million people aged 65 or over, Japan has the lowest fertility rate in the world. Older people are more susceptible to infectious diseases. In addition, the incidence of drug-resistant infectious diseases is increasing, increasing the demand for alternative treatment options.